Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 12;24(14):11336.
doi: 10.3390/ijms241411336.

The Interplay between Bioactive Sphingolipids in the Psoriatic Skin and the Severity of the Disease

Affiliations

The Interplay between Bioactive Sphingolipids in the Psoriatic Skin and the Severity of the Disease

Mateusz Matwiejuk et al. Int J Mol Sci. .

Abstract

Psoriasis is a complex chronic immunologically mediated disease that may involve skin, nails, and joints. It is characterized by hyperproliferation, deregulated differentiation, and impaired apoptosis of keratinocytes. Sphingolipids, namely ceramide, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate, are signal molecules that may regulate cell growth, immune reactions, and apoptosis. Fifteen patients with psoriasis and seventeen healthy persons were enrolled in the study. Skin samples were taken from psoriatic lesions and non-lesional areas. Tissue concentration of ceramides, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate was measured by liquid chromatography. We assessed that all levels of ceramides, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate were higher in lesioned psoriatic skin than in non-affected skin. The profile of bioactive lipids in the lesional skin of patients with psoriasis differed significantly from non-involved psoriatic skin and skin in healthy subjects.

Keywords: ceramide; psoriasis; sphinganine; sphinganine-1-phosphate; sphingosine; sphingosine-1-phosphate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Comparison between sphingolipids in healthy (CTRL), psoriatic lesional (PSO (l)), and psoriatic non-lesional (PSO (nl)) skin. (A) Amount of sphinganine (SFA) (pmol/mg of tissue). (B) Amount of sphinganine-1-phosphate (SFA1P) (pmol/mg of tissue). (C) Amount of sphingosine-1-phosphate (S1P) (pmol/mg of tissue). (D) Amount of sphingosine (SFO) (pmol/mg of tissue). (E) Amount of ceramide (CER) (pmol/mg of tissue). (F) The ratio of sphinganine and sphingosine. Significance markers: a signifies different vs. CTRL (p < 0.05) and b signifies different vs. PSO (NL) (p < 0.05).
Figure 2
Figure 2
Correlation matrix (heatmap). Pearson correlation coefficients are depicted as shades of blue (positive correlation) or red (negative correlation). (A) Correlation matrix for psoriatic non-lesional (PSO (nl)) skin. (B) Correlation matrix for psoriatic lesional (PSO (l)) skin. CER—ceramide; Desq.—desquamation; Eryth.—erythema; Ind.—induration; PASI_l—psoriasis area severity index_lesional; PASI_t—psoriasis area severity index_total; S1P—sphingosine-1-phosphate; SFA—sphinganine; SFA1P—sphinganine-1-phosphate; SFO—sphingosine.

Similar articles

Cited by

References

    1. Parisi R., Symmons D.P.M., Griffiths C.E.M., Ashcroft D.M. Global epidemiology of psoriasis: A systemic review of incidence and prevalence. J. Invest. Dermatol. 2013;133:377–385. doi: 10.1038/jid.2012.339. - DOI - PubMed
    1. Parisi R., Iskander I.Y.K., Kontopantelis E., Augustin E., Griffiths C.E.M., Ashcroft D.M. National, regional, and worldwide epidemiology of psoriasis: Systemic analysis and modeling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590. - DOI - PMC - PubMed
    1. Zheng M., Jullien D., Eyerich E. The prevalence and Disease Characteristics of generalized Pustular Psoriasis. Am. J. Clin. Dermatol. 2022;23((Suppl. S1)):5–12. doi: 10.1007/s40257-021-00664-x. - DOI - PMC - PubMed
    1. Rendon A., Schakel K. Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci. 2019;20:1475. doi: 10.3390/ijms20061475. - DOI - PMC - PubMed
    1. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873. doi: 10.1038/nature05663. - DOI - PubMed